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patients ($1,042 vs. $1,593, p0.0034). The pharmacy costswere, however, higher in
these patients, compared to SOC-initiated patients ($4,358 vs. $3,235, p0.001). In
addition, duloxetine-initiated patients were less likely to use any opioids (56% vs.
63%, p0.05) compared with SOC patients not initiated on opioids. CONCLUSIONS:
Commercially-insured CLBP patients initiating duloxetine were associated with
significantly lower inpatient costs and CLBP-related outpatient costs, but higher
pharmacy costs, compared to patients initiating other SOC treatments. Duloxetine-
initiated patients were also less likely to use opioids in the post-index year.
PSY15
LIFETIME IMPACT OF ON-DEMAND TREATMENT OPTIONS ON BLEEDING,
HOSPITALIZATION, AND QOL IN ITALIAN HEMOPHILIA PATIENTS WITH
INHIBITORS
Bilir SP1, Petrilla AA2, Trochlil K2, Weatherall J3, Lee WC2
1IMS Health Consulting Group, Redwood City, CA, USA, 2IMS Health Consulting Group,
Alexandria, VA, USA, 3Novo Nordisk A/S, Soeborg, Denmark
OBJECTIVES: The impact of on-demand (OD) treatment for bleeding episodes is
rarely quantified in Italian hemophilia patients with inhibitors. This study calcu-
lated lifetime events, hospitalizations, and quality-of-life (QoL) associated with
recombinant activated Factor VIIa (rFVIIa) and plasma-derived activated pro-
thrombin complex concentrate (pd-aPCC). This study also compared a hypotheti-
cal improved bypassing agent (BA) with faster, more sustained bleed resolution
than rFVIIa against pd-aPCC. METHODS: We developed an Italian semi-Markov
cohort model to reflect treatment effect on bleeds across a lifetime horizon for
2-year old hemophilia patients with high-responding inhibitors. The model tracks
patients through eight health states (pre-ITI, delayed ITI, ITI low dose, ITI high
dose, tolerized, partially-tolerized, non-tolerized, death) in 3-month cycles; bleeds
and treatment success are simulatedwithin states. Published international studies
informed efficacy estimates, and published utility data informed QoL parameter
values. RESULTS: In analysis of rFVIIa vs pd-aPCC, fewer rFVIIa patients required
1 series of home infusions per bleed (13% vs. 40% for pd-aPCC), leading to 4%
fewer hospitalizations following 2 unsuccessful home treatments. QALYs, de-
pendent on tolerization status in the basecase, are 43.13 for rFVIIa vs. 43.06 for
pd-aPCC. Exploratory comparison with improved rFVIIa bleed-resolution showed
reducing the rebleed rate by 15% reduces use of 1 line of therapy by 2%, decreas-
ing hospitalization 13% compared to basecase values. If fewer infusions of the new
BA are required to control a bleed per line of therapy, patients may experience QoL
benefits; utility improvement of 5%-20% raises total QALYs to 43.98-46.54 for the
new BA. CONCLUSIONS: rFVIIa may lower on-demand treatment resource use for
inhibitor patients in Italy, and improving haemostasis of BAs would further im-
prove patient care for this population; additional research around Italian treatment
patterns for inhibitor patients as well as the impact of faster bleed resolution is
warranted.
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OBJECTIVES:To systematically reviewpublished literature assessing the economic
evidence of biologic treatments indicated for Crohn’s disease (CD).METHODS: Pub-
lished articles between January 1995 and June 2011 were searched in PubMed,
EMBASE, ABI/INFORM, Tuft’s Cost-Effectiveness Analysis Registry Database, Co-
chraneNational Health Service Economic Evaluation Database, International Phar-
maceutical Abstracts, Web of Science, and Google Scholar. Studies of interest in-
cluded: 1) cost studies; 2) economic evaluations; or 3) narrative or systematic
reviews related to economic evaluations of biological treatments used for moder-
ate-to-severe CD. Exclusion criteria included the following characteristics: 1) CD-
related cost studies that were narrative or systematic reviews; 2) CD-related cost
studies that did not include costs of biologic treatments; 3) studies published only
as abstracts; or 4) non-English studies. The primary outcomes of interest included
costs associated with biological treatments and cost-effectiveness measures in-
cluding incremental cost-effectiveness ratios. A threshold value of $50,000/QALY
or £30,000/QALY was used to judge treatment cost-effectiveness. RESULTS: Twen-
ty-nine studies were identified, including 12 economic evaluations and 17 cost
studies or reviews of economic evaluations. Economic evaluation studies illus-
trated that infliximab was cost-effective compared with standard care for luminal
CD when provided as induction therapy followed by: 1) episodic therapy over 5 or
more years, or 2) maintenance therapy over one year. Additionally, adalimumab
was found to be more cost-effective than both infliximab and standard care for
luminal CD in terms of 1-year maintenance treatment with or without prior induc-
tion treatment. Cost studies revealed that infliximab usage reduced overall health-
care resource utilization and cost. Older reviews were inconclusive on the cost-
effectiveness of biologic treatments used for CD. CONCLUSIONS: Limited evidence
suggests that biologic treatments are cost-effective for CD under certain clinical
situations. Future studies are recommended to include all indicated biologic treat-
ments to provide a systematic comparison regarding their comparative benefits
and costs.
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OBJECTIVES: This retrospective study aimed to estimate the economic burden
associated with WPL in patients with psoriasis (Pso) in a US based population.
METHODS: Continuously enrolled adult patients with 2 Pso diagnoses were se-
lected from the MarketScan Claims database (2004-2008). Pso patients were
matched (based on age and gender) to continuously enrolled adult Pso-free pa-
tients (i.e., without diagnosis for Pso or psoriatic arthritis). WPL was estimated
using workplace absenteeism and short term disability (STD) expenditures avail-
able in the MarketScan Health and Productivity Management database. Only patients
for whom the employer recorded absenteeism and STD were included in the anal-
ysis. WPL, often referred to as total indirect cost, was defined as the sum of absen-
teeism costs (i.e., hours out of work for medical reasons [sick leave]* hourly wage)
and STD costs (number of days on disability * daily wage). Wages were imputed
based on the regions of residence using data from the U.S. Bureau of Labor Statis-
tics. Annual incremental costs associated with WPL in Pso patients were stratified
by Pso severity (mild or moderate-to-severe) and estimated using generalized lin-
ear models. Moderate-to-severe Pso patients were defined as patients who used
systemic therapies during the 6-month baseline period; mild Pso patients did not
use any systemic therapies during the baseline period. RESULTS: A total of 1137
matched pairs were included. Among Pso patients, 305 (26.8%) had moderate-to-
severe Pso. After adjusting for confounding factors (age and gender), no significant
cost differences associated with WPL were found when comparing mild Pso to
Pso-free patients ($1827 for mild Pso vs. $1770 for Pso-free; difference $52,
p0.825). When compared to Pso-free patients, however, moderate-to-severe Pso
patients were associated with significant incremental WPL of $1026 per patient-
year ($2781 for moderate-to-severe Pso vs. $1770 for Pso-free; p0.014).
CONCLUSIONS: Pso imparts a substantial WPL in patients with moderate-to-se-
vere Pso.
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OBJECTIVES: To estimate incremental resource use and costs of Pso and obesity in
Pso patients.METHODS: Adult Pso patients (2 Pso diagnoses) were selected from
a large US claims database (2004-2008). Pso patients were matched (based on age
and gender) to Pso-free patients (i.e., without Pso or psoriatic arthritis diagnosis).
Obesity was defined based on patients’ reported body mass index (BMI30).
Healthcare resource use and costs were assessed over a one-year period. Incidence
rate differences and incremental annual total health care costs (USD 2010; mea-
sured from a payer perspective) associated with Pso and obesity between Pso and
Pso-free patients were estimated using multivariate Poisson regression models
and generalized linear regressionmodels, respectively, controlling for age, gender,
and Charlson comorbidity index. RESULTS: A total of 1874 matched pairs with
reported BMI were selected. Among Pso patients, 34%were obese compared to 28%
of the Pso-free controls (p0.01). Compared to non-obese Pso patients, obese Pso
patients had on average 7more urgent care visits (hospitalizations and emergency
department visits) per 100 patient-years (p 0.02), and 1.8 more outpatient visits
per patient-years (p0.01). Compared to Pso-free patients, Psowas associatedwith
5.0 more outpatients visits per patient-years in non-obese patients and 6.3 more
outpatients visits per patient-year in obese patients (both p 0.01). Among Pso
patients, obesity presented a $2,729 incremental cost compared to the non-obese
Pso patients ($12,670 vs. $9,192; p0.01). Compared to Pso-free patients, Pso was
associated with a $4,735 incremental total health care cost among non-obese pa-
tients ($9,192 vs. $4,681; p0.01) and a $6,887 incremental cost among obese pa-
tients ($12,670 vs. $5,460; p0.01). The difference ($2152) between $6887 and $4735
was not statistically significant in the final model. CONCLUSIONS: Pso patients
have higher prevalence of obesity when compared to Pso-free patients. Both Pso
and obesity were associated with significant incremental costs.
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OBJECTIVES: Patients with FLT3-mutated AML have poor prognoses due to short
survival, high incidence of relapse, and a lack of effective treatment options. The
objective of this study was to review AML-related literature and estimate the eco-
nomic burden of FLT3-mutated AML in the United States.METHODS: A systematic
literature review was conducted to identify relevant publications from 2000-2011.
Estimates of the epidemiology of FLT3-mutated AML were calculated from SEER
data andUS Census projections. An Excelmodel was developed to estimate the BOI
of FLT3-mutated AML. Resource utilization estimates were obtained from the lit-
erature and expert opinion. RESULTS:A total of 607 citationswere identified and 35
articles abstracted. No direct estimates for the incidence or prevalence of FLT3-
mutated AML in the United States were identified in the literature. The prevalence
of AML in 2008 was obtained from SEER data (27,813 patients aged 20 years). In
2010, it was estimated that 784 adults 60 years and 1,622 adults 60 years were
diagnosed with FLT3-mutated AML. The BOI of FLT3-mutated AML in the US was
estimated at $251 million in 2010, including $191 million in direct costs and $60
million in lost productivity. For newly diagnosed patients60 years, the burden of
FLT3-mutated AMLwas estimated at $90million in 2010. Inpatient hospitalizations
accounted for 36% of direct costs and stem cell transplants for 38%. The cost per
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newly diagnosed FLT3-mutated AML patient 60 years was estimated at $114,193
compared to $105,819 for patients with non-FLT3-mutated AML. As early mortality
and early retirement were not included in indirect costs, these may be
underestimated. CONCLUSIONS: FLT3-mutated AML potentially represents a
greater per-patient burden than non-FLT3-mutated AML due to shorter survival
and greater use of stem cell transplants. Investigational treatments targeting the
FLT3 mutation may provide an additional therapeutic option and have the poten-
tial to improve clinical outcomes.
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OBJECTIVES: Hemophilia patients frequently experience joint bleeding, resulting
in persistent pain and arthropathy. The objective of this study was to determine
drivers of total and hemophilia-related costs among hemophilia patientswith joint
pain.METHODS: InVision™ Data Mart (OptumInsight Life Sciences, 1/2005-3/2009)
was used to identify male patients with hemophilia A/B (ICD-09 286.0 and 286.1)
who were treated with FVIII/FIX/bypassing agent and had  2 years of continuous
enrollment from index. Patients were stratified into severe joint pain (SJP), 2 joint
pain claims (ICD-9 713, 715, 716, 718, 719, 727) 12 months pre or 6 months post
index, andminimal joint pain (MJP), 2 pain claims. Cohorts werematched on age,
treatment type and Charlson comorbidity scores via propensity scoring. Random
forest analysis informed covariate selection for log-transformed linear regression
models. Covariate selection was further refined based on variance inflation, vari-
able significance and medical relevance. RESULTS: A total of 284 patients (142 SJP,
142 MJP); mean age30 years were identified. Mean (median) total cost of all pa-
tients was $630K ($248K) over a 2-year period but were significantly higher for SJP-
$917K compared to MJP- $354K (p0.01). Hemophilia therapy was the main driver
of total patient cost (p0.0001). Home health visits (p0.0001), hemophilia-related
hospital visits (p0.0001) and age (p0.01) were also significant drivers of SJP costs.
Removal of covariates measuring factor therapy or claims with hemophilia diag-
noses showed that joint pain claims (p0.01), injectible medications (p0.01),
Charlson Comorbidity Index (p0.01), non-hemophilia lab tests (p0.01), anti-in-
fective medications (p0.01), and age (p0.001) were significantly related to total
patient cost.CONCLUSIONS:The treatment of joint painmarks significantly higher
hemophilia costs, however, some of these differences may be attributed to hemo-
philia severity (not coded within ICD-9). Modification of ICD-9 codes may help
understand economics among hemophilia patients in the future.
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OBJECTIVES: Postherpetic neuralgia (PHN) is a painful, chronic condition. Gabap-
entin and pregabalin are common first-line medications for PHN and must be
titrated over time to effective doses. Individuals with PHN may augment therapy
with opioids to control pain. Pain management for PHN can require substantial
healthcare resources. The study objective was to evaluate costs for persons with
PHN. METHODS: This retrospective claims database analysis used medical and
pharmacy claims data and enrollment information for adult commercial andMedi-
care Advantage enrollees in a large, national US health plan. Patients had1 phar-
macy claim for gabapentin or pregabalin from January 2006–February 2009; the
date of the first claimwas the index date. Patients also had diagnosis codes for PHN
(ICD-9-CM 053.1x) on or within 2 days after the index date; and 6-month and 12-
month pre- and post-index periods, respectively, during which they were contin-
uously enrolled. Total medical, outpatient pharmacy, and health care (medical 
pharmacy) post-index costs per patient with PHN per month were compared be-
tween gabapentin and pregabalin cohorts. RESULTS: The study population com-
prised 1645 patients, 939 in the gabapentin cohort and 706 in the pregabalin cohort;
77.6% were commercial enrollees and 22.4% were Medicare Advantage enrollees.
The mean (standard deviation) monthly healthcare costs were $1,749 ($6,117) for
the gabapentin cohort and $1,570 ($4,935) for the pregabalin cohort (p0.512).Mean
monthly medical costs were $1326 ($5831) in the gabapentin cohort and $985
($4,753) in the pregabalin cohort (p0.192). The pregabalin cohort had highermean
monthly pharmacy costs ($585 [$727]) than did the gabapentin cohort ($423 [$755],
p0.001). CONCLUSIONS: Health care costs for patients with PHN are substantial:
approximately $1700 per person with PHN per month, and approximately $20,000
per year. Health care costs between the gabapentin and pregabalin cohorts were
not significantly different despite significantly different mean pharmacy costs.
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OBJECTIVES: Prior research evaluated the impact of infliximab (IFX) adherence on
resource use and costs in Crohn’s disease (CD). Purpose was to examine the asso-
ciation between adherence and all-cause healthcare costs among those who are
treatedwith IFX for inflammatory bowel disease (IBD).METHODS: Patients with1
claims for IFX initiated between January 1, 2006 to December 31, 2009 who had 2
IBD diagnoses of Crohn’s disease (CD; ICD-9-CM: 555.XX) or ulcerative colitis (UC;
ICD-9-CM: 556.XX) during the pre-index period were identified from Thomson Reu-
ters Marketscan® Databases. Patients had to be 18 years, continuously enrolled for
12 months before and after IFX initiation, and had no prior use of IFX during 360-
days pre-index. Patients with prior biologic therapy or rheumatoid arthritis (ICD-
9-CM: 714.XX) were excluded. Adherent group was classified as having a medica-
tion possession ratio (MPR) of 80%; non-adherent group had an MPR80%.
Differences between the adherent and non-adherent groups were assessed using
propensity-weighted general linear models. RESULTS: A total of 1,646 IBD patients
were identified (945 CD; 701 UC) with a mean (SD) age of 44.4 (15.6) and 48.3% were
female. Of these, 41% were adherent and 59% were non-adherent. Propensity-
weighted mean total healthcare costs excluding IFX were $13,424 vs. $32,522
(P0.0001) for the adherent vs. non-adherent groups. Mean all-cause component
costs were $2,458 vs. $17,634 (P0.0001) for hospitalizations, $7,357 vs. $10,909
(P0.0001) for outpatient visits, and $236 vs. $458 (P0.0001) for ER visits in the
adherent vs. non-adherent groups, respectively; total costs (component IFX)were
also significantly lower in the adherent group. No significant differences were ob-
served in other prescription costs. CONCLUSIONS: Medication adherence was as-
sociated with significantly lower total healthcare costs in patients treated with IFX
for IBD. These differencesmay be explained by reducedhospitalization, outpatient,
and ER costs observed in the adherent vs. non-adherent groups.
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OBJECTIVES: Little data are available on the burden of ASM, a subtype of systemic
mastocytosis (SM) and severe form of mast cell disease that may progress to mast
cell leukemia. This study reviewed the literature in order to estimate the burden of
ASM in theUS.METHODS:Asystematic literature reviewwas conducted to identify
publications from2000-2011; 181 citationswere identified and 6 articles abstracted.
TheUS population-level burden of ASMwas estimated using an Excelmodel. Direct
treatment costs were calculated from treatment patterns described in identified
publications. RESULTS: ASM involves multiple organ systems, resulting in poten-
tially severe symptoms/conditions including anaphylaxis/allergic reactions, osteo-
porosis, hepatomegaly, splenomegaly, gastrointestinal symptoms, fatigue, and
weight loss. There is no known cure for ASM. Median survival was 41 months in a
published cohort study. No publicationswere identified providingUS epidemiology
data. Two estimates were calculated for the prevalence of ASM in the US in 2010:
616 and 1,220. A global prevalence rate of 0.2/100,000 resulted in 616 cases. An SM
prevalence rate of 3.3/100,000 (assuming 12% ASM) resulted in 1,220 cases. Inci-
dence was estimated at 111 cases in 2010 using an SM incidence rate of 0.3/100,000
(assuming 12% ASM). The proportion of ASM/SM cases ranged from 7-18% in the
literature with 12% from the largest study. No studies were identified examining
the economic burden of ASM. In this model, direct monthly per-patient costs were
estimated between $5232 and $8741. These are likely underestimated as a result of
limited resource utilization information in the literature. CONCLUSIONS: These
results provide preliminary estimates for the burden of ASM in the UNITED
STATES. Additional research can assist in further quantifying these estimates. In
addition, it is likely that ASM patients experience tremendous indirect costs due to
the symptomatic burden of the disease and further evaluation is warranted.
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OBJECTIVES: To evaluate the association of patient cost or reimbursement chal-
lenges with healthcare resource utilization, quality of life (QoL), and work produc-
tivity among patients with inflammatory bowel disease (IBD).METHODS: A syndi-
cated study of IBD patients in the USwas conducted. Patients18 years of agewere
recruited via the National Health and Wellness Survey and Lightspeed Research
Panel. Patients completed a survey during August–November 2010 in which they
were asked if they experienced cost or reimbursement challenges related to pre-
scription medication. The Medical Outcomes Study (MOS) IBD questionnaire was
used to assess QoL. Work productivity was assessed using the Work Productivity
and Activity Impairment (WPAI) questionnaire. To measure health care resource
utilization, the number of provider, emergency room (ER) and hospital visits in the
past six months was collected. Bivariate differences between the patient groups
(those with cost or reimbursement issues versus those without) for resource utili-
zation, QoL, and work impairment were assessed using chi-square tests for cate-
gorical variables and t-tests for continuous variables. RESULTS: Of 1098 IBD pa-
tients currently receiving prescription medication, 21% (n231) reported that cost
had previously prevented them from taking medication. Among patients who had
ever taken prescription medication (n1343), 13% (n178) reported ever having a
problem getting reimbursed for medication. Sixty-eight of these patients (38%)
indicated theirmedicationwas not covered by insurance. Patients reporting cost or
reimbursement issues had a higher probability of having provider, ER and hospital
visits in the prior six months (all p0.05). Furthermore, these patients reported
greater work impairment and lower QoL (both p0.05). CONCLUSIONS:Among IBD
patients, cost or reimbursement challenges may be associated with more resource
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